Literature DB >> 10650158

Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans.

M Fujita1, N P Verhoeff, A Varrone, S S Zoghbi, R M Baldwin, P A Jatlow, G M Anderson, J P Seibyl, R B Innis.   

Abstract

The effect of endogenous dopamine on in vivo measurement of dopamine D(2) receptors in extrastriatal regions (thalamus and temporal cortex) was evaluated with single photon emission computed tomography and the high affinity ligand [123I]epidepride by comparing the binding potential before and after acute dopamine depletion. Dopamine depletion was achieved by per-oral administration of 5.5 g/70 kg body weight alpha-methyl-para-tyrosine given in 37 h. The alpha-methyl-para-tyrosine treatment increased the binding potential significantly in the temporal cortex (13+/-15%, P=0.036) but not in the thalamus (2+/-9%). The increase of the binding potential in the temporal cortex correlated strongly with the increase of dysphoric mood evaluated by the Positive and Negative Symptom Scale (PANSS) (rho=0.88, P=0.004). These results imply that [123I]epidepride, coupled with acute dopamine depletion might provide estimates of synaptic dopamine concentration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10650158     DOI: 10.1016/s0014-2999(99)00817-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457.

Authors:  Sargo Aalto; Anna Brück; Matti Laine; Kjell Någren; Juha O Rinne
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

2.  Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Authors:  Sargo Aalto; Jouni Ihalainen; Jussi Hirvonen; Jaana Kajander; Harry Scheinin; Heikki Tanila; Kjell Någren; Harry Vilkman; Lars L Gustafsson; Erkka Syvälahti; Jarmo Hietala
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

3.  Midbrain dopamine D2/3 receptor binding in schizophrenia.

Authors:  Heli Tuppurainen; Jyrki T Kuikka; Mikko P Laakso; Heimo Viinamäki; Minna Husso; Jari Tiihonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-16       Impact factor: 5.270

Review 4.  Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging.

Authors:  Ji Hyun Ko; Antonio P Strafella
Journal:  Neuroscientist       Date:  2011-05-02       Impact factor: 7.519

5.  Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease.

Authors:  Ji Hyun Ko; Francesca Antonelli; Oury Monchi; Nicola Ray; Pablo Rusjan; Sylvain Houle; Anthony E Lang; Leigh Christopher; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2012-02-14       Impact factor: 5.038

Review 6.  Neuroleptic dysphoria: towards a new synthesis.

Authors:  L Voruganti; A G Awad
Journal:  Psychopharmacology (Berl)       Date:  2003-11-27       Impact factor: 4.530

Review 7.  New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.

Authors:  Stephanie M Perez; Daniel J Lodge
Journal:  Drug Des Devel Ther       Date:  2014-07-02       Impact factor: 4.162

8.  AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures.

Authors:  Erik Boot; Jan Booij; Gregor Hasler; Janneke R Zinkstok; Lieuwe de Haan; Don H Linszen; Thérèse A van Amelsvoort
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-19       Impact factor: 9.236

Review 9.  Abnormal striatal dopamine transmission in schizophrenia.

Authors:  Jerome Brunelin; Shirley Fecteau; Marie-Françoise Suaud-Chagny
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

10.  In vivo absolute quantification of striatal and extrastriatal D2/3 receptors with [123I]epidepride SPECT.

Authors:  Stergios Tsartsalis; Benjamin B Tournier; Philippe Millet
Journal:  EJNMMI Res       Date:  2020-06-16       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.